CreatSens Health was aimed to provide a unique paper-based potassium and creatinine potentiometric sensor solution helping the healthcare professional to better manage the information that can be generated in primary care centres, doctor’s office or patient’s home. Biochemical and physical information will be integrated in a technological platform allowing to predict, early detect and to prevent acute conditions from home.
With real-time biomarkers information, specialists would greatly reduce the progression of the disease. CreatSens Health has established agreements with several Key Opinion Leaders (KOL) in nephrology and cardiology. After a first round of intensive meetings in order to introduce the concept, approach and technology to the medical community, the team now leads a project to run a collaborative test to validate both the technology and the medical hypothesis.
CreatSens has diversified core and lateral markets. Core to the value proposition is the antihypertensive drugs market, which covers diseases such as chronic kidney diseases and cardiovascular complications. This is a high-volume market. Needs and benefits were detected in the healthcare medical devices market, especially from the nephrological point of view, where potassium and creatinine determinations create high value to support decision makers.
Regarding the lateral markets, it comprises the fields of radiotherapy and cardiology imaging, diabetic nephropathy and bipolar disorder. In radiotherapy and cardiology imaging, we detect the need of in-situ creatinine analysis before a Computed Axial Tomography scan (CAT scan).
The expected potential impact will:
• Provide a fast (results in <5 minutes), painless and easy to use monitoring system for CKD.
• Increase the quality of life (Qol) of patients by improving the monitoring quality of their CKD. We provide an effective solution available to patients where and when they need it. Reduce of acute episodes and increase of the efficacy of treatments through consistent monitoring and re-adjustment of pharmaceutical doses, diet and exercise (personalized care).
• Reduces direct healthcare costs related to CKD management by 30% by delaying the start of dialysis. We will contribute to a more efficient and sustainable healthcare system.
• Reduces waiting time in hospitals by more than 20%, which means a positive impact on the patient’s productivity and/or active life: wellbeing .
All this is possible thanks to the unique combination of real-time monitoring diagnostics tools in combination with predictive software analyses.
